Compare TPCS & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPCS | PRPO |
|---|---|---|
| Founded | 1956 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.1M | 42.0M |
| IPO Year | 2008 | 2000 |
| Metric | TPCS | PRPO |
|---|---|---|
| Price | $5.80 | $27.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 59.3K | ★ 131.5K |
| Earning Date | 02-17-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.38 | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,644,000.00 | $24,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $2.88 | $16.01 |
| 52 Week High | $6.31 | $33.63 |
| Indicator | TPCS | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 57.14 | 51.57 |
| Support Level | $4.41 | $25.95 |
| Resistance Level | $5.69 | $29.20 |
| Average True Range (ATR) | 0.24 | 2.27 |
| MACD | -0.05 | -0.18 |
| Stochastic Oscillator | 40.34 | 40.06 |
Techprecision Corp manufactures precision, large-scale fabricated and machined metal structural components and systems. The company provides end-to-end services, transforming raw materials into precision finished products through custom fabrication, precision machining, assembly, integration, inspection, non-destructive evaluation, and testing. It manufactures products in accordance with customers' drawings and specifications while complying with applicable national and international industry codes and standards. Its segments are: Ranor, which generates the majority of revenue, and Stadco, both focused on the manufacture and assembly of components mainly for defense and other precision industrial customers.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.